BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/10/2023 7:29:15 AM | Browse: 128 | Download: 238
 |
Received |
|
2022-11-29 04:33 |
|
Peer-Review Started |
|
2022-11-29 04:35 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-02-08 02:41 |
|
Revised |
|
2023-02-16 07:43 |
|
Second Decision |
|
2023-02-24 04:09 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-02-27 21:54 |
|
Articles in Press |
|
2023-02-27 21:54 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-03-06 02:34 |
|
Typeset the Manuscript |
|
2023-03-07 08:32 |
|
Publish the Manuscript Online |
|
2023-03-10 07:29 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Systemic treatment for metastatic colorectal cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana, Pathomthep Leowattana and Tawithep Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, BMed, MD, MSc, PhD, Full Professor, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi Road, Bangkok 10400, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
Systemic treatment; Metastatic colorectal cancer; Personalized medicine; Biomarkers; Chemotherapy; Targeted therapy; Immunotherapy |
| Core Tip |
Advances in molecular profiling of metastatic colorectal cancer allow treatment to be tailored to the biologic characteristics of the tumor for certain patient subgroups. Although cures are still rare, more people can expect to live longer. Genomic profiling enables therapy selection, allowing more individuals to benefit while exposing fewer to the harm of ineffective medicines. An important component in determining treatment results is the choice of an effective first-line therapy, which should consider both clinical considerations and molecular indicators. The systemic treatments used in the first-line regimen determine the second-line regimen. Third-line therapy, which includes epithelial growth factor receptor inhibitors for patients with rat sarcoma virus wild-type, should consider molecular profiling. Patients with high microsatellite instability illnesses may be candidates for immunotherapy with pembrolizumab or nivolumab plus ipilimumab. |
| Publish Date |
2023-03-10 07:29 |
| Citation |
Leowattana W, Leowattana P, Leowattana T. Systemic treatment for metastatic colorectal cancer. World J Gastroenterol 2023; 29(10): 1569-1588 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i10/1569.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i10.1569 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
